Universal Health Services Inc (UHS) Stock Analysis and Metrics

Universal Health Services

NYSE: UHS

$151.17 ▼ -2.37 (-1.54%)

At close: Jul 17, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap9.19 Bn

P/E6.05

P/S0.52

Div. Yield0.01

ROIC (Qtr)-0.01

Total Debt (Qtr)4.71 Bn

Revenue Growth (1y) (Qtr)9.65

Add ratio to table…

About

Universal Health Services Inc is a healthcare company that owns and operates acute care hospitals, outpatient facilities, and behavioral health care facilities through its subsidiaries. As of February 25, 2026, the company operated 375 inpatient facilities and 168 outpatient and other facilities across 40 states, Washington D. C., the United Kingdom, and Puerto Rico. The company’s core activities include providing general and specialty surgery, internal medicine, obstetrics, emergency care, radiology, oncology, diagnostic services, coronary care, pediatrics, pharmacy, and behavioral health services.

Universal Health Services Inc generates revenue primarily from patient services rendered at its hospitals and outpatient facilities, including payments from private insurers, managed care plans, Medicare, Medicaid, and self-pay patients. The company also derives revenue from its commercial health insurer operations and management services provided to its facilities. Net revenues from acute care hospitals, outpatient facilities, and the commercial health insurer accounted for approximately 57% of consolidated net revenues in both 2025 and 2024, while behavioral health care facilities and the commercial health insurer contributed approximately 43% during the same periods. Behavioral health care facilities in the United Kingdom generated net revenues of about $1.001 billion in 2025 and $880 million in 2024.

Universal Health Services Inc operates through two main business segments: acute care hospitals and behavioral health care facilities.

• Acute care hospitals: This segment includes inpatient acute care hospitals, free-standing emergency departments, outpatient centers, and a surgical hospital. As of the reporting date, the segment comprised 29 inpatient acute care hospitals, 35 free-standing emergency departments, 13 outpatient centers, and one surgical hospital located in the United States. Services provided encompass general and specialty surgery, internal medicine, obstetrics, emergency room care, radiology, oncology, diagnostic care, coronary care, pediatric services, pharmacy services, and behavioral health services.

• Behavioral health care facilities: This segment provides inpatient and outpatient behavioral health services across the United States, the United Kingdom, and Puerto Rico. In the U. S., it includes 182 inpatient and 110 outpatient facilities; in the U. K., 161 inpatient and 2 outpatient facilities; and in Puerto Rico, 3 inpatient and 7 outpatient facilities. The segment delivers psychiatric care, substance use treatment, counseling, and related therapeutic services to patients with mental health and emotional disorders.

Universal Health Services Inc holds a significant position in the U. S. healthcare industry as one of the largest owners and operators of hospital facilities, particularly in the behavioral health sector where it maintains a leading market share. The company competes with other for-profit hospital operators, nonprofit health systems, and government-owned facilities, differentiating itself through its integrated model of acute and behavioral health services, centralized management support, and focus on community-based care. Its scale, geographic diversification, and compliance infrastructure provide competitive advantages in navigating regulatory environments and securing managed care contracts.

Universal Health Services Inc serves a broad customer base including patients seeking acute medical treatment, individuals requiring behavioral health services, and beneficiaries of government healthcare programs such as Medicare and Medicaid. The company also works with private insurance providers, managed care organizations, and employers who purchase health benefits for their employees. Its facilities are utilized by individuals across diverse demographic and socioeconomic groups in the communities where they operate.

Investment Thesis

▲ Bull case

The Talkspace acquisition adds a national virtual outpatient platform with six thousand licensed clinicians across all fifty states which creates a foundation for an end to end continuum of behavioral health care that links lower acuity services with the company’s existing residential and inpatient capabilities. This continuum enables the firm to capture patients stepping down from higher levels of care and to offer them a preferred virtual option that improves continuity of care and drives higher quality outcomes. Management highlighted bidirectional revenue synergies such as introducing Talkspace clinicians into hospital environments to develop higher acuity virtual intensive outpatient programs which can generate additional fees while utilizing existing clinical infrastructure. The deal is expected to be accretive to earnings in the first twelve months post close and to become increasingly accretive thereafter with an effective EBITDA multiple projected to reach single digit levels by year three.
The company has deployed and scaled eight AI use cases in revenue cycle operations that are already delivering measurable benefits in denials management and revenue capture which directly improve cash flow and reduce administrative expense. For 2026 the focus shifts to clinical operations where AI solutions are being built with partners such as Hippocratic AI to enhance hospital level efficiency and patient experience without yet touching core clinical decision making. These initiatives are expected to be incremental to margins over time while also delivering non financial gains in quality and patient satisfaction that can strengthen the firm’s reputation and payer relationships. Because the AI investments leverage existing technology infrastructure the marginal cost of scaling additional use cases remains low which supports sustained operating leverage as volume grows.
Universal Health Services maintains a robust share repurchase program with approximately one point three billion dollars of authorization remaining and has consistently returned capital to shareholders through buybacks and dividends as evidenced by the recently declared twenty cent per share dividend. The board’s commitment to returning capital signals confidence in free cash flow generation and does not preclude further mergers acquisitions or capital expenditures because the company recently expanded its credit facilities by nine hundred million dollars to provide additional financial flexibility. This balanced approach allows the firm to pursue strategic growth opportunities such as the Talkspace deal while still delivering attractive shareholder returns and maintaining a leverage profile that remains comfortable for future financing needs. The combination of active buybacks and a growing dividend yield can support the stock price even if operational growth experiences short term volatility.
The behavioral health segment is experiencing a structural shift toward outpatient delivery which aligns with broader industry trends and is being supported by the company’s investment in freestanding outpatient clinics under the Thousand Branches initiative and the newly acquired Talkspace platform. This outpatient focus enables the firm to capture rising demand for lower acuity services while reducing reliance on more capital intensive inpatient beds and thereby improving operating leverage as volumes increase. Recent de novo hospital openings in states such as Pennsylvania Missouri and Florida are adding capacity that will mature over the next twelve to eighteen months and contribute to earnings once stabilization periods are completed. Management expects volume growth to accelerate as weather related disruptions subside and as staffing initiatives from 2025 begin to yield better retention and productivity gains which together should drive same facility revenue growth beyond the low single digit levels seen in the first quarter.

The Talkspace acquisition adds a national virtual outpatient platform with six thousand licensed clinicians across all fifty states which creates a foundation for an end to end continuum of behavioral health care that links lower acuity services with the company’s existing residential and inpatient capabilities. This continuum enables the firm to capture patients stepping down from higher levels of care and to offer them a preferred virtual option that improves continuity of care and drives higher quality outcomes. Management highlighted bidirectional revenue synergies such as introducing Talkspace clinicians into hospital environments to develop higher acuity virtual intensive outpatient programs which can generate additional fees while utilizing existing clinical infrastructure. The deal is expected to be accretive to earnings in the first twelve months post close and to become increasingly accretive thereafter with an effective EBITDA multiple projected to reach single digit levels by year three.
The company has deployed and scaled eight AI use cases in revenue cycle operations that are already delivering measurable benefits in denials management and revenue capture which directly improve cash flow and reduce administrative expense. For 2026 the focus shifts to clinical operations where AI solutions are being built with partners such as Hippocratic AI to enhance hospital level efficiency and patient experience without yet touching core clinical decision making. These initiatives are expected to be incremental to margins over time while also delivering non financial gains in quality and patient satisfaction that can strengthen the firm’s reputation and payer relationships. Because the AI investments leverage existing technology infrastructure the marginal cost of scaling additional use cases remains low which supports sustained operating leverage as volume grows.
Universal Health Services maintains a robust share repurchase program with approximately one point three billion dollars of authorization remaining and has consistently returned capital to shareholders through buybacks and dividends as evidenced by the recently declared twenty cent per share dividend. The board’s commitment to returning capital signals confidence in free cash flow generation and does not preclude further mergers acquisitions or capital expenditures because the company recently expanded its credit facilities by nine hundred million dollars to provide additional financial flexibility. This balanced approach allows the firm to pursue strategic growth opportunities such as the Talkspace deal while still delivering attractive shareholder returns and maintaining a leverage profile that remains comfortable for future financing needs. The combination of active buybacks and a growing dividend yield can support the stock price even if operational growth experiences short term volatility.
The behavioral health segment is experiencing a structural shift toward outpatient delivery which aligns with broader industry trends and is being supported by the company’s investment in freestanding outpatient clinics under the Thousand Branches initiative and the newly acquired Talkspace platform. This outpatient focus enables the firm to capture rising demand for lower acuity services while reducing reliance on more capital intensive inpatient beds and thereby improving operating leverage as volumes increase. Recent de novo hospital openings in states such as Pennsylvania Missouri and Florida are adding capacity that will mature over the next twelve to eighteen months and contribute to earnings once stabilization periods are completed. Management expects volume growth to accelerate as weather related disruptions subside and as staffing initiatives from 2025 begin to yield better retention and productivity gains which together should drive same facility revenue growth beyond the low single digit levels seen in the first quarter.

▼ Bear case

The expiration of Affordable Care Act subsidies and ongoing Medicaid disenrollment are creating a rising tide of health insurance exchange volume declines that the company currently estimates will affect pretax earnings by about seventy five million dollars for the full year but which could deepen as more exchange members fail to sustain premium payments. Management has acknowledged that the effective decline in exchange volume may be in the low double digits in the first quarter and could reach twenty five to thirty% over the remainder of the year which would increase bad debt reserves and uncompensated care costs beyond the current guidance. Higher bad debt directly impacts net income and could erode the earnings accretion expected from the Talkspace acquisition if the trend continues to worsen. Because the company’s reserve methodology is already conservative any further deterioration would likely require additional provisions that would surprise investors who are assuming a stable impact from the subsidy expiration.
Wage growth in behavioral health remains a significant challenge as the company expects year over year increases of approximately six% which while moderating from the seven to eight% levels seen in 2025 still puts pressure on operating margins especially in markets where staffing shortages persist. The firm has reported progress in reducing turnover from peak levels but industry wide turnover remains elevated and the cost of recruiting and retaining nurses therapists and mental health technicians continues to rise. Any slowdown in the expected moderation of wage increases would force the company to either absorb higher labor costs or to limit hiring which could constrain volume growth in both outpatient and inpatient settings. Because labor is a major component of expense in the behavioral segment sustained wage pressure could offset the benefits of volume growth and impede the segment’s ability to deliver the targeted EBITDA expansion.
The company’s earnings guidance assumes a meaningful contribution from supplemental payment programs such as disproportionate share hospital payments and other state specific arrangements which have historically provided a sizable boost to EBITDA but are subject to the timing and approval processes of individual states. Recent commentary indicated that while the pending 2025 program in Florida is viewed favorably the timing remains uncertain and the California program lacks consensus between state regulators and CMS which creates a risk of delayed or reduced benefits. If these supplemental payments fail to materialize as expected the company would lose a source of earnings that has been used to offset seasonal volume softness and to support the targeted five% core EBITDA growth for the year. Investors who rely on the stability of these payments may be overestimating the predictability of cash flow from this component of the business.
The ongoing rollout of de novo hospital projects including the 156 bed facility in Florida the 178 bed expansion in California Las Vegas and Florida and the 144 bed joint venture hospital in Pennsylvania requires substantial upfront capital expenditure and typically generates an operating loss during the initial months of operation. While management expects losses at new Florida and Pennsylvania facilities to be offset by gains at more mature assets such as Cedar Hill in Washington DC the timing of that offset is uncertain and could extend beyond the current fiscal year if ramp up is slower than anticipated. The capital intensity of these projects also means that cash flow from operations may be diverted to fund construction which limits the amount available for debt reduction or shareholder returns in the short term. Consequently the near term earnings profile could be softer than models that assume immediate contribution from new capacity leading to potential disappointment if investors anticipate a quicker accretive impact.

The expiration of Affordable Care Act subsidies and ongoing Medicaid disenrollment are creating a rising tide of health insurance exchange volume declines that the company currently estimates will affect pretax earnings by about seventy five million dollars for the full year but which could deepen as more exchange members fail to sustain premium payments. Management has acknowledged that the effective decline in exchange volume may be in the low double digits in the first quarter and could reach twenty five to thirty% over the remainder of the year which would increase bad debt reserves and uncompensated care costs beyond the current guidance. Higher bad debt directly impacts net income and could erode the earnings accretion expected from the Talkspace acquisition if the trend continues to worsen. Because the company’s reserve methodology is already conservative any further deterioration would likely require additional provisions that would surprise investors who are assuming a stable impact from the subsidy expiration.
Wage growth in behavioral health remains a significant challenge as the company expects year over year increases of approximately six% which while moderating from the seven to eight% levels seen in 2025 still puts pressure on operating margins especially in markets where staffing shortages persist. The firm has reported progress in reducing turnover from peak levels but industry wide turnover remains elevated and the cost of recruiting and retaining nurses therapists and mental health technicians continues to rise. Any slowdown in the expected moderation of wage increases would force the company to either absorb higher labor costs or to limit hiring which could constrain volume growth in both outpatient and inpatient settings. Because labor is a major component of expense in the behavioral segment sustained wage pressure could offset the benefits of volume growth and impede the segment’s ability to deliver the targeted EBITDA expansion.
The company’s earnings guidance assumes a meaningful contribution from supplemental payment programs such as disproportionate share hospital payments and other state specific arrangements which have historically provided a sizable boost to EBITDA but are subject to the timing and approval processes of individual states. Recent commentary indicated that while the pending 2025 program in Florida is viewed favorably the timing remains uncertain and the California program lacks consensus between state regulators and CMS which creates a risk of delayed or reduced benefits. If these supplemental payments fail to materialize as expected the company would lose a source of earnings that has been used to offset seasonal volume softness and to support the targeted five% core EBITDA growth for the year. Investors who rely on the stability of these payments may be overestimating the predictability of cash flow from this component of the business.
The ongoing rollout of de novo hospital projects including the 156 bed facility in Florida the 178 bed expansion in California Las Vegas and Florida and the 144 bed joint venture hospital in Pennsylvania requires substantial upfront capital expenditure and typically generates an operating loss during the initial months of operation. While management expects losses at new Florida and Pennsylvania facilities to be offset by gains at more mature assets such as Cedar Hill in Washington DC the timing of that offset is uncertain and could extend beyond the current fiscal year if ramp up is slower than anticipated. The capital intensity of these projects also means that cash flow from operations may be diverted to fund construction which limits the amount available for debt reduction or shareholder returns in the short term. Consequently the near term earnings profile could be softer than models that assume immediate contribution from new capacity leading to potential disappointment if investors anticipate a quicker accretive impact.

Peer Comparison

Companies in the Medical Care Facilities

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	HCA	HCA Healthcare, Inc.	87.94 Bn	11.25	1.15	48.02 Bn
2	CHE	Chemed Corp	18.08 Bn	51.68	7.12	0.09 Bn
3	THC	Tenet Healthcare Corp	16.59 Bn	9.74	0.77	13.21 Bn
4	DVA	Davita Inc.	15.37 Bn	14.02	1.10	10.63 Bn
5	EHC	Encompass Health Corp	10.07 Bn	654.20	1.66	2.57 Bn
6	ENSG	Ensign Group, Inc	9.52 Bn	27.18	1.81	0.14 Bn
7	UHS	Universal Health Services Inc	9.19 Bn	6.05	0.52	4.71 Bn
8	PACS	PACS Group, Inc.	6.96 Bn	28.55	1.28	0.05 Bn

Research Tools

Developers

About

Investment Thesis

Consolidation Items Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Consolidation Items Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password